Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
amU1uB8K1dACG5zZ
Listen
